chylomicronemia syndrome


Also found in: Dictionary, Thesaurus, Encyclopedia.
Related to chylomicronemia syndrome: familial chylomicronemia syndrome

chylomicronemia syndrome

Hyperchylomicronemia A condition characterized by marked chylomicronemia with plasma TG levels > 225 mmol/L–US: 2000 mg/dL Clinical Abdominal and chest pain, pancreatitis, memory defects, carpal tunnel-like paresthesiae, hepatosplenomegaly, chronic eruptive xanthomata, and insulin-resistant DM, possibly related to marked hypertriglyceridemia; Sx are exacerbated by alcohol, β blockers, diuretics, estrogens, glucocorticoids

chylomicronemia syndrome

(kīl″ō-mī″krō-nēm′ē-ă) [″ + ″ + ″]
A disorder of lipid metabolism in which massively elevated levels of triglycerides are accompanied by the presence of chylomicrons in the blood, even after a fast. It results in abdominal pain, eruptive xanthomas, hepatosplenomegaly, memory loss, and occasionally, life-threatening pancreatitis. The syndrome may result from congenital deficiencies or inhibition of lipoprotein lipase; from apolipoprotein deficiency; or from diseases or conditions that elevate plasma triglyceride levels (poorly controlled diabetes mellitus; excessive ingestion of alcohol; the use of some drugs).
Mentioned in ?
References in periodicals archive ?
Diagnostic algorithm for familial chylomicronemia syndrome. Atheroscler Suppl.
This was also the first time I heard the term familial chylomicronemia syndrome (FCS), which is a term used to describe LPLD and the other mutations that can cause this syndrome.
Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome. In: Scriver C, Baudet A, Sly W, Valle D, eds.
The product is intended for the treatment of patients with Familial Chylomicronemia Syndrome. FCS is a rare genetic disease characterized by extremely high triglyceride levels and risk of pancreatitis.
Akcea Therapeutics announced the publication of results from the first-ever study demonstrating the benefits of patient-to-patient connectivity in the management of familial chylomicronemia syndrome. FCS is a rare, potentially life-threatening disease with multiple severe, daily and chronic manifestations that affect one's ability to work and engage in activities of everyday living.
M2 EQUITYBITES-July 7, 2015-Akcea Therapeutics wins US FDA's orphan drug designation for Volanesorsen for treating Familial Chylomicronemia Syndrome
Akcea Therapeutics (AKCA), up 11% after an FDA advisory committee voted 12-8 to support approval of volanesorsen for the treatment of people with familial chylomicronemia syndrome. DOWN AFTER EARNINGS: Nvidia (NVDA), down 2.5%...
The most advanced drug in its pipeline, volanesorsen, has successfully completed a Phase 3 clinical program for the treatment of familial chylomicronemia syndrome, or FCS, and is currently in Phase 3 clinical development for the treatment of familial partial lipodystrophy, or FPL.
Drug company Isis Pharmaceuticals (NasdaqGS:ISIS) announced on Thursday that it has initiated a Phase 3 study evaluating ISIS-APOCIIIRx in patients with familial chylomicronemia syndrome (FCS), a rare orphan disease that is characterised by extremely high triglyceride levels.